Pfizer Glucotrol XL Patent Should Be Deemed Late Listed – Andrx
Executive Summary
FDA should deem a patent on Pfizer's Glucotrol XL "late-listed," even if it is reissued and listed in the "Orange Book," Andrx says in a 1citizen petition
You may also be interested in...
Andrx settles Glucotrol infringement suit
Andrx agrees with Pfizer and Alza to settle patent infringement litigation over the company's ANDA for a generic version of Glucotrol XL (glipizide extended release). All claims were dropped with Andrx agreeing to receive a royalty-bearing sublicense under relevant Alza patents. Andrx believes it was first to file a glipizide ANDA. Andrx filed a citizen's petition with FDA related to the case in November (1"The Pink Sheet" Nov. 11, 2002, p. 25)...
Andrx settles Glucotrol infringement suit
Andrx agrees with Pfizer and Alza to settle patent infringement litigation over the company's ANDA for a generic version of Glucotrol XL (glipizide extended release). All claims were dropped with Andrx agreeing to receive a royalty-bearing sublicense under relevant Alza patents. Andrx believes it was first to file a glipizide ANDA. Andrx filed a citizen's petition with FDA related to the case in November (1"The Pink Sheet" Nov. 11, 2002, p. 25)...
Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Waxman/Hatch language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification